Due to budget constraints, steep cuts to Medicaid benefits are likely in the short term. This may come in the form of even more severe limits on coverage of obesity meds.
for 2025-2026 that eliminates Medicaid coverage for GLP-1 agonists for weight loss. Other states are considering similar cuts. States areto close gaps in budgets. Enactment of The Big Beautiful Bill will likely add pressure on budget finances.
It’s hard to envision a scenario in which state Medicaid agencies expand coverage of weight loss treatments in the short term.Medications known as glucagon-like peptide-1 agonists, or GLP-1s, have become very popular as weight loss agents. Taken in accordance with the instructions on the label and an appropriate diet and exercise regimen, GLP-1s are effective at lowering a person’s weight. However, payers in both the commercial and public sectors often balk at coverage. Commercial insurance coverage is improving but stillIn the federal insurance program for the elderly and some disabled persons, Medicare, coverage of GLP-1s for weight loss alone is prohibited, though obese patients can get the semaglutide-based product, Wegovy, covered for heart disease.for obesity medications or have already done so, whether in the Medicaid program itself or state employee plans. For example, North Carolina and West Virginia have recently eliminated coverage of GLP-1s for weight loss for state employees due to cost concerns.in federal budget outlays as a result of passage of The Big Beautiful Bill, it is likely more states will follow suit. The law severely restricts how states pay for their share of Medicaid costs. To illustrate, states have long used healthcare provider taxes and certain special payment arrangements to fund their portion of the program. Yet the new legislationStates that do opt to cover various weight loss treatments, including medications, nutrition programs and bariatric surgery, almost invariably deploy restrictive eligibility requirements around things like body mass indices and the presence of co-morbidities, along with the use of prior authorization and step edits. This means, for instance, that individuals wanting to access treatments must attest to “increased exercise activity” and submit documentation proving that they’ve tried and failed to lose weight after receiving nutrition counseling and going on a strict, low-calorie diet. In light of budget constraints, steep cuts to a wide range of Medicaid benefits are probable in the short term. This may come in the form of even more severe limits on coverage of medicines and other healthcare technologies, including obesity treatments. It’s possible that through a voluntary demonstration project that the Centers for Medicare and Medicaid Services announced last month, some state Medicaid agencies could soon elect to cover these drugs for “.” But the plan has not been finalized. Nor have any details been divulged besides the fact that it would commence in April of next year for Medicaid. Without information on how state programs would be incentivized to sign up, it’s unclear who would be interested. The perennial issue for all types of payers is money. Once these therapeutics are covered by insurance, they tend to blow up budgets. Many payers in the commercial sector cite serious budgetary concerns. Areleased this spring of employer-based plans shows that GLP-1 drugs used for obesity account for an average of 10.5% of total annual claims. And if Medicare were to lift its prohibition on coverage, it would cost the program a cumulative. While the estimates included possible savings from improved health, these were not nearly sufficient to offset the costs of the medications. Such projected expenses haven’t been calculated specifically for Medicaid. But the churn or enrollee turnover is so high in Medicaid that any longer-term, downstream cost savings would be very hard to come by, further exacerbating the budgetary problem. While cost is a primary consideration for payers, lack of persistence on GLP-1s is another reason for hesitance to reimburse weight loss drugs. Patients who are treated with GLP-1s tend to discontinue at a relatively high rate. One study cited by federal government policymakers found that approximately 53% of patients with overweight or obesity taking semaglutide-based products didn’t persist on treatment past two months. Starting and stopping on these medicines so soon yields little or no benefit to patients and only adds costs for payers. It’s possible that employers, commercial insurers and payers in the public sector—including Medicaid—decide to eventually revisit their coverage decisions if net prices of GLP-1s decrease sufficiently, combined with more data showing the benefits of weight loss drugs when taken consistently and persistently in conjunction with an appropriate dietary and exercise regimen. Until that time, however, coverage will continue to be a major hurdle.
Medicare GLP-1S Weight Loss Drugs Insurance Coverage Commercial Plans Wegovy Zepbound Obesity Discontinuation
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
CVS Caremark drops coverage of popular weight loss drugPharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay programs at $499 monthly
Read more »
Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverageWeight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those with previous adverse reactions.
Read more »
Medicaid, Medicare may cover weight loss drugs under new pilot program: reportBlockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.
Read more »
Trump Administration Considers Pilot Program to Cover Weight Loss Drugs for Medicare and Medicaid PatientsThe Trump administration is planning a five-year pilot program to provide access to weight loss drugs like Ozempic and Wegovy for obese individuals enrolled in Medicare and Medicaid.
Read more »
Trump Administration mulls Pilot Program for Weight Loss Drugs on Medicare and MedicaidThe Trump administration is considering a five-year pilot program to provide access to weight loss drugs like Ozempic and Wegovy for obese individuals enrolled in Medicare and Medicaid. The program, if approved, would allow states to cover these medications for weight management purposes, marking a shift from the previous stance of not covering them solely for weight loss. The proposal remains under development and could undergo further public feedback before implementation.
Read more »
Trump Administration to Pilot Medicare and Medicaid Coverage for Weight Loss DrugsThe Trump administration is planning a pilot program that would allow Medicare and Medicaid recipients to access popular weight loss drugs like Ozempic and Wegovy.
Read more »